Welcome to our dedicated page for ARGENT BIOPHARMA news (Ticker: MGCLF), a resource for investors and traders seeking the latest updates and insights on ARGENT BIOPHARMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ARGENT BIOPHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ARGENT BIOPHARMA's position in the market.
Summary not available.
MGC Pharmaceuticals Ltd. has announced that its investigational medicinal product, CannEpil®, is now available to patients in the UK through Named Patient Request. This decision follows the success of Epidiolex, which generated $296 million in sales in 2019, highlighting the potential market for CannEpil® in treating refractory epilepsy. CannEpil®, a high-CBD and low-THC formulation, is currently in clinical development and has already been prescribed to hundreds of patients in Australia and the Republic of Ireland. The company aims to evaluate the safety and efficacy of CannEpil® through data collected from ongoing patient use, supporting future marketing authorization submissions. This expansion into the UK market represents a significant step for MGC Pharma and offers new treatment options for patients with unmet medical needs.
MGC Pharmaceuticals Ltd. (LSE: MXC, OTC: MGCLF) announced that its product ArtemiC™ is now listed as an OTC drug in the US, according to the FDA National Drug Code (NDC) Database. This milestone, facilitated by US partner AMCPharma USA, allows ArtemiC™ to enter US Pharmacy Benefit Management (PBM) networks by April 2023. AMC has placed a US$2 million order, with deliveries scheduled for Q3 and Q4 2023. ArtemiC™, which has shown effectiveness in treating moderate COVID-19 and chronic inflammatory diseases, was developed with Grat Bio® SNEDD technology, ensuring high bioavailability and safety.
MGC Pharmaceuticals Ltd. (OTC: MGCLF) has signed an exclusive distribution agreement with Sciensus Rare to distribute its products, CannEpil® and CogniCann®, in key European markets and the UK. This partnership aims to enhance access to CannEpil®, for drug-resistant epilepsy, and CogniCann®, for dementia and Alzheimer's patients. The agreement covers several countries including Denmark, France, Italy, Spain, Luxembourg, and the UK for an initial four years. MGC Pharma remains responsible for market authorization, while Sciensus Rare handles early access program applications.